Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
N.J. Goodson, N.J. Wiles, M. Lunt, E.M. Barrett, A.J. Silman, D.P. Symmons.
Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients.
Arthritis Rheum, 46 (2002), pp. 2010-2019
[2.]
E.J. Kroot, M.A. Van Leeuwen, M.H. Van Rijswijk, M.L. Prevoo, M.A. Van’t Hof, Van De Putte, et al.
No increased mortality in patients with rheumatoid arthritis: up to 10 years of follow up from disease onset.
Ann Rheum Dis, 59 (2000), pp. 954-958
[3.]
M. Boers, B. Dijkmans, S. Gabriel, H. Maradit-Kremers, J. O’Dell, T. Pincus.
Making an impact on mortality in rheumatoid arthritis: targeting cardiovascular comorbidity.
Arthritis Rheum, 50 (2004), pp. 1734-1739
[4.]
N. Goodson.
Coronary artery disease and rheumatoid arthritis.
Curr Opin Rheumatol, 14 (2002), pp. 115-120
[5.]
N.J. Goodson, D.P. Symmons, D.G. Scott, D. Bunn, M. Lunt, A.J. Silman.
Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort.
Arthritis Rheum, 52 (2005), pp. 2293-2299
[6.]
H. Maradit-Kremers, C.S. Crowson, P.J. Nicola, K.V. Ballman, V.L. Roger, S.J. Jacobsen, et al.
Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study.
Arthritis Rheum, 52 (2005), pp. 402-411
[7.]
I. González-Álvaro, L. Carmona, A. Balsa, R. Sanmartí, M.A. Belmonte, X. Tena.
Patterns of disease modifying antirheumatic drug use in a Spanish cohort of patients with rheumatoid arthritis.
J Rheumatol, 30 (2003), pp. 697-704
[8.]
N. Goodson, J. Marks, M. Lunt, D. Symmons.
Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s.
Ann Rheum Dis, 64 (2005), pp. 1595-1601
[9.]
I. Del Rincón, R.W. Haas, S. Pogosian, A. Escalante.
Lower limb arterial incompressibility and obstruction in rheumatoid arthritis.
Ann Rheum Dis, 64 (2005), pp. 425-432
[10.]
K.J. Warrington, P.D. Kent, R.L. Frye, J.F. Lymp, S.L. Kopecky, J.J. Goronzy, et al.
Rheumatoid arthritis is an independent risk factor for multi-vessel coronary artery disease: a case control study.
Arthritis Res Ther, 7 (2005), pp. R984-R991
[11.]
S. Van Doornum, B. King, C. Brand, V. Sundarajan.
Mortality rates following a first acute cardiovascular event. A comparison between rheumatoid arthritis patients and the general population [abstract].
Arthritis Rheum, 52 (2005), pp. 2
[12.]
B. Masdottir, T. Jonsson, V. Manfredsdottir, A. Vikingsson, A. Brekkan, H. Valdimarsson.
Smoking, rheumatoid factor isotypes and severity of rheumatoid arthritis.
Rheumatology (Oxford), 39 (2000), pp. 1202-1205
[13.]
S.P. Linn-Rasker, A.H. Van der Helm-van Mil, F.A. Van Gaalen, M. Kloppenburg, R.R. De Vries, S. Le Cessie, et al.
Smoking is a risk factor for anti- CCP antibodies only in rheumatoid arthritis patients who carry HLADRB1 shared epitope alleles.
Ann Rheum Dis, 65 (2006), pp. 366-371
[14.]
I. Del Rincón, K. Williams, M.P. Stern, G.L. Freeman, D.H. O’Leary, A. Escalante.
Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects.
Arthritis Rheum, 48 (2003), pp. 1833-1840
[15.]
L.T. Jacobsson, W.C. Knowler, S. Pillemer, R.L. Hanson, D.J. Pettitt, R.G. Nelson, et al.
Rheumatoid arthritis and mortality. A longitudinal study in Pima Indians.
Arthritis Rheum, 36 (1993), pp. 1045-1053
[16.]
R.B. Landewe, F.C. Breedveld, BA. Dijkmans.
Methotrexate treatment and mortality in rheumatoid arthritis.
Lancet, 360 (2002), pp. 1095-1096
[17.]
I.D. Del Rincón, K. Williams, M.P. Stern, G.L. Freeman, A. Escalante.
High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors.
Arthritis Rheum, (2001), pp. 2737-2745
[18.]
L.T. Jacobsson, C. Turesson, R.L. Hanson, et al.
Joint swelling as a predictor of death from cardiovascular disease in a population study of Pima Indians.
Arthritis Rheum, 44 (2001), pp. 1170-1176
[19.]
L.A. García Rodríguez, A. González-Pérez.
Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population.
BMC Med, 3 (2005), pp. 17
[20.]
I. Del Rincón, D.H. O’Leary, R.W. Haas, A. Escalante.
Effect of glucocorticoids on the arteries in rheumatoid arthritis.
Arthritis Rheum, 50 (2004), pp. 3813-3822
[21.]
H.K. Choi, M.A. Hernan, J.D. Seeger, J.M. Robins, F. Wolfe.
Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study.
Lancet, 359 (2002), pp. 1173-1177
[22.]
L. Colglazier, F. Wolfe, K. Michaud.
Rheumatoid arthritis (RA) patients are less likely to be treated with prophylactic aspirin despite an increased risk of myocardial infarction.
Meeting of the American College of Rheumatology [abstract],
[23.]
H. Maradit-Kremers, P.J. Nicola, C.S. Crowson, K.V. Ballman, S.E. Gabriel.
Cardiovascular death in rheumatoid arthritis: a population-based study.
Arthritis Rheum, 52 (2005), pp. 722-732
[24.]
D.W. McCarey, I.B. McInnes, R. Madhok, R. Hampson, O. Scherbakov, I. Ford, et al.
Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial.
Lancet, 363 (2004), pp. 2015-2021
[25.]
E. Krishnan, J.F. Fries.
Reduction in long-term functional disability in rheumatoid arthritis from 1977 to 1998: a longitudinal study of 3035 patients.
Am J Med, 115 (2003), pp. 371-376
Copyright © 2006. Elsevier España S.L. Barcelona
